SAVA - Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?

2024-03-17 09:42:44 ET

Summary

• Cassava Sciences presented different charts at the CTAD and Lisbon conferences, causing speculation about the reasons for the discrepancy.
• Cassava Sciences combined some mild Alzheimer's disease patients with mild cognitive impairment patients and others with moderate Alzheimer's disease patients in the first chart.
• Cassava Sciences provided scores for mild cognitive impairment and moderate Alzheimer's disease patients in the second chart, but provided no scores for mild Alzheimer's disease patients.
• Simufilam has little effect on moderate Alzheimer's disease, keeps those with mild Alzheimer's disease near baseline for one year, and those with mild cognitive impairment near baseline for two years.
• The Food and Drug Administration may approve simufilam for the treatment of mild cognitive impairment, but if it does it is difficult to predict the market reaction to a company whose drug was once supposed to cure or at least modify Alzheimer's disease.

Cassava Sciences ( SAVA ) recently presented a chart at the Alzheimer’s and Parkinson’s Diseases Conference in Lisbon that did not match the chart that it had presented at the Clinical Trial on Alzheimer’s Disease Conference (CTAD) held in Boston last year. This set off a small flurry of speculation as to the reasons for the mismatch; all the way from the benign ( different statistical modeling ) to the manipulative ( missing patient data ). In this article, I will explain the reason for the discrepancy between the two charts and what it likely means for Cassava Sciences' future....

For further details see: